 |
Our Metabolic Amplification Platform Technology |
|
Due to the very broad nature of the underpinnings of
our discoveries and developments thus far, it is important to note that the ongoing
outcomes being established impact on a very vast array of aspects
relative to just about every industry sector, including from the
most basic of R&D processes through to how end products and services
are utilised. However, due to our current financial, legislative and other general restrictions the best avenue for further research, development and application has been in relation to that of the field of therapeutic substances. As such, we have been developing a therapeutics based platform technology that incorporates all of our new discoveries to be able to substantially enhance the capabilities of treatment methodologies. Our Metabolic Amplification Platform TechnologyEssentially, almost all medical conditions are the result of one or more of 3 main contributing factors. These 3 factors are: 1) dysfunctional cell receptors; 2) unbalanced biochemical systems; and 3) mutated gene sequence attributes. Due to our breakthrough findings and the ongoing further research and development that we have been conducting we now behold the knowledge of how to develop treatments to rectify any of these factors as they relate to just about any known human medical condition! In essence, what we have discovered is that there are a number of key systems at the most primary levels of biological functioning in the human body (including at a genetic level) that control how literally any substance is assimilated into and utilised by the human body. As such, this information has allowed for a revolutionary new Metabolic Amplification Platform Technology to be commenced to be developed that caters for the discovery and development of numerous highly advanced and safe treatments. Our breakthrough Metabolic Amplification Platform not only ensures that the human body utilises substances far more safely but also far more effectively and far more efficiently. In fact, by utilising our new discoveries and developments most all side effects and other general complications and inadequacies can be greatly controlled and/or minimised, and, in many instances, even completely eradicated. All this, in turn, means that, due to this new knowledge, the time frames, regulatory formalities and costs associated with fully developing new treatments to commercial roll out (as well as that of many of the other new technologies that will evolve) can now be substantially reduced. In fact, after initial discussions with regulatory consultants, we are confident that most new treatments will now take around just 3 to 5 years to fully develop and commercialise – compared to the current average industry time frame of a very lengthy 9 to 15 years! At the end of the day, what all of this means is that much cheaper, better and safer therapeutics can be produced. New Capabilities In Biological ControlAs a subsequence of our breakthrough discoveries as a whole we are now rapidly developing the ability to actually program protein synthesis, pathway metabolism, cell receptor activity and so on in a manner much the same as that in which computer programmers program the various levels of functioning within a computer! Hence, what we are now able to do is:
The following are examples of how these 3 methods of biological control as well as our technologies in general can be utilised to produce more effective, efficient and safer treatment outcomes: 1. Cell ReceptorsOne of the most primary breakthrough discoveries we have made is that of establishing how to recalibrate cell receptors that have become dysfunctional due to receptor hypertrophy and hyperplasia so as to inhibit medical conditions that relate to such (such as autoimmune diseases, diabetes, drug addictions and so on). What's more, this same know how can also be utilised to increase cell receptor activity levels for the purposes of many types of general biological enhancement. Furthermore, we have also even discovered how to silence many genetic mutations using receptor agonists and/or antagonists so as to inhibit the symptoms and general pathogenesis of medical conditions relative to cell receptor dysfunction. As a further extension of these new understandings we have also discovered that many of the problems associated with therapeutic substances are caused by these substances not being properly assimilated into their relative cell receptors. As such, we have now also established how to assimilate any substance into its correctly associated cell receptors with 100% accuracy! What this means is that the assimilation methods of currently utilised therapeutics can be altered to allow them to properly bind to their intended cell receptors whilst any new substances can be readily developed with the proper and accurate cell receptor assimilation already in consideration. What's more, many substances that showed great promise but either did not make it very far through the development cycle or were dropped quite far into the development cycle due to any of the common and/or uncommon and/or even unexplainable problems can be reassessed to determine if the issues involved were simply due to the substances not being properly assimilated into their relative cell receptors. And, as such, many of these substances can then be resurrected and fully developed into viable therapeutics. Furthermore to all of this, we have also discovered that some of our newly discovered metabolic networks are designed to target very limited and highly specific types of cell receptors. As such, many new receptor targets can be established along with the development of many new therapeutics for these new targets. 2. Recycling Pathways & Metabolic BalancingIt is well noted and accepted that, due to the metabolic manipulation involved with many therapeutic substances, many metabolites and waste products can and usually do build up to toxic levels which, in themselves, can and usually do cause many other problems. As an extension of our main discoveries we have uncovered that components of metabolic waste products can be extracted and recycled back into the pathways and general biological systems that require them so as to further enhance and/or extend therapeutic methods and targeting. As such, we have now established how to utilise numerous newly discovered and already established recycling systems and their control mechanisms so as to both enhance and extend therapeutic capabilities. What's more, we have also discovered that these recycling systems can and do, under very specific circumstances, also act as substitutes for other primary metabolic pathways and signal transduction systems. However, there are a number of genetic and epigenetic factors that must be pre-established before these recycling and substitute metabolic systems and networks will come into play – thus why other scientists currently have not be able to, and will not been able to, readily or easily establish the same outcomes in their laboratories. In fact, it is important to note that even if anyone in the industry or scientific community in general were to start working out aspects of the breakthroughs discussed on this website – and regardless of whether or not they were actually aware of the information on this website – the findings would not be able to be properly implemented without the knowledge of our delivery method and other pertinent aspects that we have been discussing. Though it varies depending on each individual case, the capabilities of our newly discovered recycling systems can be utilised as isolated methods and/or in synergism with other substances and methods. Having said all of this, our investigations into many already established treatments in relation to these recycling systems and their control mechanisms have thus far demonstrated significant potentiation and longevity of these treatments, as well as substantially reducing most all relevant side effects and toxicity rates. Furthermore, our investigations into recycling pathways and metabolic homeostasis have also demonstrated that major improvements to already existing treatments can be achieved through combination therapy. It is important to note that this can and will be especially useful for circumstances requiring that 'extra edge' and/or a reduction in ill-effects and/or in relation to medical conditions that require substantially lengthy and ongoing treatment. Yet again, our initial investigations into this kind of combination therapy have thus far demonstrated significant potentiation and longevity of such treatments as well as substantially reducing many relevant side effects and toxicity rates. Furthermore, our newly established knowledge concerning recycling pathways can also be utilised in general to help re-establish properly balanced biochemical systems so as to inhibit medical conditions that relate to such (such as certain types of heart and brain diseases, certain types of gout, many types of immune deficiencies, and so on) – and whether induced by particular types of treatment methods, genetic predispositions, poor diet or any other relevant circumstance. 3. Genetic Mutations & System DysfunctionsAlthough there is still much room for further investigation, we have been able to establish that our breakthroughs as a whole are capable of silencing mutated gene sequences and specific types of SNP’s (Single Nucleotide Polymorphisms) whilst also being able to amplify the necessary gene expressions required to inhibit medical conditions and the general biological systemic dysfunctions that relate to such (such as certain types of cancers, reduced gene expression rates resulting in the poor metabolism of certain substances, and so on). Furthermore, in many instances, long term ongoing treatments can also be devised that will, over time, result in genetic and general systemic biological changes that will protect against relevant medical conditions either occurring or reoccurring. What's more, these changes can also protect against related and other new conditions arising. It is important to note that these capabilities actually relate, in many instances, to established knowledge and/or proposed theories surrounding these kinds of capabilities. With the science community's ongoing investigations into fields of study such as nutritional genomics, personalised medicine and preventative health we are slowly – but surely – adding more and more to our genetic silencing and reprogramming knowledge and capabilities. FurthermoreIt is also important to note that, by combining all of this knowledge together, and where the diagnosed need is ascertained, dosage rates can also usually be increased substantially past currently prescribed rates yet without any toxicity or other ill-effects occurring. What's more, in many instances dosage levels can actually be substantially reduced yet with the same or better therapeutic affects. To most, this kind of technological know how would probably seem extremely 'high tech' and difficult to understand and therefore quite difficult to put into practice. However, the later is not true. In fact, although the underlying technological know how is quite high tech, the end products that people will be utilising to treat their problems are relatively quite easy to understand and follow. Furthermore, for the most part the treatments simply involve 'popping pills' just like with any other type of medicine based treatment. We also strongly believe that our treatments will greatly serve to substantially minimise the need for surgical and other highly invasive or risky procedures. Essentially, the reason that the mechanisms we have been researching and forming our developments around have such a profound and vast impact is due to the fact that, as mentioned earlier, the mechanisms operate at very primordial levels of functioning within both the human genome and the human body in general. We Are But Mere Computer-Like Biological MachinesAll in all, the general ability to recognise, boost, manipulate and cater for the expressions of any biochemical system as well as that of any relative general biological system within the human body coupled with the ability to generally control production, utilisation and directional flow rates of biochemical constituents has been established. One way of looking at all of our new understandings and capabilities is that of imagining, completely hypothetically, that there are, say, 10 levels of control mechanisms and systems within the human genome and metabolic expression, and, that, it could be said, the industry is currently working at about level 3 within this hierarchy whereas the level our discoveries work at are at about level 8. Furthermore, the levels that we are working within are also subdivided into grouped systems with individual yet highly coordinated control mechanisms that function both independently and, as required, cooperatively with each other to both enhance and better manage overall biological functioning. Thus, the systems, mechanisms and so on we are working with are at a far greater primary level and thus control not only the systems, mechanisms and so on currently being utilised by the industry but also many, many other systems, mechanisms and so on within the human body and its general biological functioning that, at present, are not currently known and/or understood by the scientific community. And, we are slowly – but surely – bridging the (hypothetical) gap between level 3 and level 8 thus paving the way for many more extraordinary new understandings and accomplishments, and, therefore, making our current already established understandings and accomplishments literally only the tip of the iceberg for what is to come in both the near and ongoing future. Having said all of this, our research and development is also focused on novel understandings and application of specific mechanisms of gene expression regulation cascades, of which also both directly and profoundly control and influence the results therapeutic methods produce. Essentially, it is both important to note and interesting to note that we are but mere computer-like biological machines that can be programmed in a very similar way to that of digital computers – except that we utilise a chemical based programming language instead of a mechanical switch based one. So, in essence, what our Metabolic Amplification Platform technology enables us to do is to program the 'data' involved with human metabolic processes in much the same way as what a computer user can program data in software, such as a spreadsheet, to perform its required tasks and operations. Now, with all of this in mind, it is also important to note that our Metabolic Amplification Platform technology will also take the emerging field of personalised medicine into a whole new level of understanding and practice. |
|
| .......................................... | |
| Members Area | |
| Retrieve Password | |
| Menu | |
 |
Introduction |
|
|
Our Newly Discovered Metabolic Networks |
|
|
Our Metabolic Amplification Platform Technology |
|
|
Nutraceutical Applications |
|
|
Pharmaceutical Applications |
|
|
Phytoceutical Applications |
|
|
Zooceutical Applications |
|
|
R & D Applications |
|
|
Diagnostic Applications |
|
|
Our Medical Treatments |
|
|
Advanced Hydrocolloids |
|
|
Partnering With Us |
|
|
Technology Pipeline |